Comparative Pharmacology
Head-to-head clinical analysis: APRETUDE versus FORTOVASE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: APRETUDE versus FORTOVASE.
APRETUDE vs FORTOVASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Apretude (cabotegravir) is an HIV-1 integrase strand transfer inhibitor (INSTI) that inhibits the integration of HIV-1 DNA into host genomic DNA, which is essential for viral replication. It binds to the active site of integrase and blocks the strand transfer step of retroviral DNA integration.
Saquinavir is a protease inhibitor that binds to the active site of HIV-1 protease, blocking the cleavage of viral polyprotein precursors into functional proteins, resulting in the production of immature, non-infectious viral particles.
600 mg IM every 2 months, initiated as two consecutive monthly loading doses of 600 mg each, for HIV-1 pre-exposure prophylaxis.
1200 mg orally three times daily with food.
None Documented
None Documented
Terminal elimination half-life is approximately 40 hours following subcutaneous injection, supporting monthly dosing.
Terminal elimination half-life is 1-2 hours in healthy subjects; prolonged to 2-5 hours in patients with hepatic impairment or when coadministered with ritonavir.
Renal (approximately 30% as unchanged drug) and fecal (approximately 50% as metabolites and unchanged drug) following oral administration.
Primarily hepatic metabolism via CYP3A4; 2% excreted unchanged in urine, 15% unchanged in feces; extensive biliary excretion of metabolites.
Category C
Category C
Antiretroviral
Antiretroviral